LB1   Protein Design of an HIV-1 Entry Inhibitor

LB2   High Viremia in HIV-Infected Patients is Associated with an Increase in a Subpopulation of Highly Dysfunctional B Cells Expressing Reduced Levels of CD21

LB3   Segregated Evolution of HIV-1 in Renal Epithelial Cells from Patients with HIV Associated Nephropathy (HIVAN)

LB4   Protease Inhibitor Resistant HIV-1 Has Marked Decreased Fitness in vivo

LB5   A Controlled Phase II Trial Assessing Three Doses of T-20 in Combination with Abacavir, Amprenavir, Low Dose Ritonavir and Efavirenz in Non-Nucleoside Naïve Protease Inhibitor Experienced HIV-1 Infected Adults

LB6   Clinical Benefit of Early Initiation of HAART in Patients with Asymptomatic HIV Infection and CD4 Counts >350/mm³

LB7   Report of Results of PACTG 316: An International Phase III Trial of Standard Antiretroviral (ARV) Prophylaxis plus Nevirapine (NVP) for Prevention of Perinatal HIV Transmission

LB8   Decreases in Total Body Bone Mineral Content Progress with Age in HIV-infected Children

LB9   HAART-Associated Bone Mineral Loss through Increased Rate of Bone Turnover in Vertically HIV-Infected Children

LB10   Prevalence of Insulin Resistance in HIV-infected PI-treated and Non-PI-treated Patients